Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9322335 | Fertility and Sterility | 2005 | 4 Pages |
Abstract
We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2α-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2α-isoprostanes after 3 or 6 months of treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Pilar J. B.Sc., Carlos M.D., Ph.D., Juan J. Ph.D., Antonio M.D., Ph.D.,